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Abstract 
Biodegradable chitosan–magnetic graphene quantum dot (MGQD) nanocomposites were 
prepared and investigated for the release of small and large molecular weight (MWt) 
therapeutics from detachable and non-detachable biodegradable microneedle arrays. The 
presence of MGQDs in chitosan increased the electrical conductivity and biodegradation rate 
of chitosan whilst maintaining its mechanical properties. The detachable microneedle arrays 
were created by including a water-soluble ring of poly(ethylene glycol) (PEG) at the base of 
the microneedle, which enabled the rapid detachment of the microneedle shaft from the base. 
The PEG ring did not impede the microneedle array performance, with mechanical properties 
and a drug release profile of low MWt lidocaine hydrochloride similar to microneedle arrays 
without the ring. Without the PEG ring, the chitosan–MGQD microneedles were electrically 
conductive and allowed for electrically stimulated release of large MWt therapeutics which 
was challenging without the stimulation. These results demonstrate that chitosan 
nanocomposites containing MGQDs with intrinsic photoluminescent and supermaganetic 
properties are promising materials for developing multifunctional microneedles for targeted 
and tracked transdermal drug delivery. 
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Introduction 
Chemically oxidised graphene, known as graphene oxide (GO) [1] has been researched as a 
drug carrier that may work more efficiently than free therapeutics [2,3], as a biosensor to 
detect a wide range of items such as the rotavirus [4], and glucose [5], as a photothermal 
ablation agent against cancer tumours [6], and as fluorescent imaging agents [7]. Graphene–
based nanoparticles have been integrated into polymers to form nanocomposites that can be 
used for drug delivery, such as the electrically stimulated release of dexamethasone [8] and 
the pH-sensitive release from a hydrogel of GO and gelatin [9]. Chitosan was used as the 
polymer matrix for nanocomposites containing GO [10] and reduced graphene oxide (rGO) 
[11] for transdermal drug delivery. These nanocomposites possessed better mechanical 
properties and improved drug release profiles over pristine chitosan, as well as novel 
functionality such as pH-sensitive release, and electrical conductivity [10,11].  
 Other nanoparticles that are of interest to nanomedicine include magnetic quantum 
dots (MQDs) that can be synthesised by doping quantum dots (QDs) of cadmium–selenium 
(Cd–Se) or cadmium–telluride (Cd–Te) with manganese [12] or cobalt [13], or by 
encapsulating magnetite or CdSe in silica spheres [14]. The delivery of the drug could be site 
specific as the MQDs could be manipulated by magnetic fields. Recently, QDs made from 
rGO chemically coated with iron oxide (from herein known as magnetic graphene quantum 
dots, MGQDs) were reported by our group [3], and were shown to be of low toxicity at low 
concentrations, photoluminescent, and superparamagnetic to form a system which allows for 
both targeted and tracked drug delivery. Chitosan–GQD nanocomposite microneedles were 
also prepared by our group that allowed for the passive release of lidocaine hydrochloride 
(LH) and the electrically stimulated release of bovine serum albumin (BSA) [15]. These 
nanocomposites possessed higher electrical conductivity than pristine chitosan and allowed 
for photoluminescent tracking/imaging of the therapeutic [15]. 
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 Strong, biodegradable polymer nanocomposites could find use in microneedle arrays 
for transdermal drug delivery. Chitosan was selected as the biodegradable polymer matrix to 
manufacture nanocomposite microneedles because it is biocompatible, renewable (sourced 
from chitin extracted from the shells of sea crustaceans), and easy to process [16]. Typically, 
microneedle arrays are solid, conical microstructures with dimensions less than one 
millimetre. Microneedle arrays use the conical projections to pierce through the stratum 
corneum (SC) and to expose the viable epidermis, a region with numerous blood vessels but 
no nerves [17]. Microneedles have a high level of patient compliance with minimal irritation 
to the skin or pain to the patient [18], and offer enhanced immune response to vaccinations 
than conventional hypodermic injection [19] and the ability to deliver a wide range of 
therapeutics, for example desmopressin [20] and insulin [21]. 
 The release of the encapsulated therapeutic from polymer microneedle arrays 
typically is dependent upon the biodegradation (for example, polylactide) or the dissolution 
rate of the polymer within bodily fluids. If these rates are too slow, it will need long treatment 
times to give the required dosage, in which case the prolonged placement of the microneedle 
patch on the skin may cause irritation and/or impede the healing process of the SC [22]. To 
counter this problem, microneedle arrays have been developed with detachable microneedles 
that will stay in the body after the backing patch has been removed, such as arrowhead–
shaped microneedles tips that detach from the main microneedle shaft when it is removed 
from the body [23]. But these approaches limit the size of the therapeutic dosage delivered as 
the drug is limited to just the arrowhead tip and not the shaft, and may also incur extra costs 
for manufacturing and assembling the arrowheads. 
 The aim of this work is to develop a novel multifunctional microneedle system with a 
simple detachable design for future targeted and tracked transdermal drug delivery, based on 
biodegradable chitosan and photoluminescent and superparamagnetic iron oxide–graphene 
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quantum dot nanocomposites.  The new design of the microneedle array allows for the quick 
separation of the microneedle shafts from the base, while maintaining the capability of the 
main shaft to encapsulate a large amount of therapeutic. MGQDs were synthesised and 
characterised in our previous work [3], utilising hydrothermal reduction of GO–IO to form 
sub 50 nm magnetic QDs. The MGQDs were combined with chitosan to form 
nanocomposites of various concentrations which were structurally characterised, and 
analysed for electrical, mechanical and biodegradation behaviour. The optimal 
nanocomposite was then chosen as the material to create multifunctional microneedle arrays, 
which were tested for mechanical integrity under standard skin-insertion loading conditions, 
as well as delivery of small and large molecular weight (MWt) therapeutics with and without 
application of an electrical stimulus. The creation of a detachable microneedle system was 
achieved through the introduction of a disc section at the base of the microneedle shaft that 
was made from a water soluble biopolymer poly(ethylene glycol) (PEG); the PEG can be 
rapidly dissolved by the body fluid which allows for the microneedles to detach from the base 
patch enabling the removal of the patch soon after its application. The effect of this new 
additional ring on the mechanical and drug release behaviour of the original microneedle 
array was assessed. 
Experimental 
Materials 
The following chemicals were reagent grade and used as purchased from Sigma Aldrich; 
acetic acid (>99.7%), sulphuric acid (95–98%), hydrogen peroxide (29–32% in H2O), 
potassium permanganate (97%), sodium nitrate (>99%), lidocaine hydrochloride (LH, 
>99%), ferrous chloride tetrahydrate (FeCl2–4H2O, >99%), ferric chloride hexahydrate 
(FeCl3–6H2O, 97%), fluorescein sodium (FL), lysozyme (from chicken egg white, ~100,000 
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U mg–1),  fluorescein sodium labelled–bovine serum albumin (BSA), PEGs (MWt’s = 10k, 
20k and 35k Da) and graphite powder (≤20 µm). Chitosan (MWt = 100k–300k Da, Acros 
Scientific) and phosphate buffered saline (PBS) tablets (pH = 7.4) were purchased from 
Fisher Scientific. 
Preparation of MGQDs  
The method to prepare MGQDs has been described in our previous work [3]. Briefly, GO 
was synthesised from graphite using a modified Hummers method [1], purified and exfoliated 
in distilled water, and lyophilised in a freeze drier (Labconco FreeZone Triad). FeCl2–4H2O 
(5.4 g) and FeCl3–6H2O (4 g) were dissolved in 135 ml distilled water. GO (1 g) was 
sonicated in 150 ml distilled water for 1 h, and ammonium hydroxide was used to raise the 
pH to 8. The iron salt solution and the GO suspension were added together and the pH was 
raised to 10 by ammonium hydroxide. Under a nitrogen atmosphere, the mixture was stirred 
for 2 h, and the resultant precipitate, GO–IO, was washed with distilled water and ethanol. 
GO–IO was dispersed in distilled water (~3 mg ml–1), and the suspension was hydrothermally 
reduced in a Parr Series 4000 autoclave (200 oC for 10 h at 1.6 MPa). A dialysis bag (Fisher 
Scientific Biodesign Dialysis tubing, MWt cut off = 3.5k) was used to separate the quantum 
dots from larger particles. MGQDs were collected from the surrounding suspension and 
lyophilised for further use.  
Drug loading onto MGQDs 
Equal quantities of MGQD and either LH or BSA were added to distilled water to form an 
aqueous suspension of 0.1 mg ml–1 and stirred for 48 h. To remove the unbound therapeutic, 
the suspension was centrifuged (8000 rpm for 1 h) and dispersed in fresh distilled water 
several times. The resultant powder was lyophilised for use. 
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Preparation of chitosan–MGQD nanocomposites 
The required amount (to form 0.25–5 wt.% nanocomposites) of the QDs (MGQD, MGQD–
LH or MGQD–BSA) was dispersed with stirring and sonication in distilled water. 
Simultaneously, chitosan was added to 2 wt.% acetic acid in distilled water to form a 2 wt.% 
solution. When the chitosan was fully dissolved (typically left overnight at room temperature 
under stirring), the MGQD suspension was added under intense stirring and left stirring 
uncovered to allow the suspension to increase in viscosity (chitosan concentration of ~80 mg 
ml–1). The mixture was degassed in a vacuum oven for 1 h at room temperature and poured 
into a mould to air dry.  
Characterisation of nanocomposites 
Fourier transform infra-red (FT-IR) spectroscopy was achieved with a resolution of 1 cm–1 
between 400–4000 cm–1 on a Perkin Elmer Spectrum 100 with a diamond attenuated total 
reflectance (ATR) unit. X-ray diffraction (XRD) analysis on a Stoe Stadi P with Cu Kα 
irradiation (0.154 nm wavelength) was performed at 40 kV and 35 mA with a scanning speed 
of 1 o min–1. 
 A Hounsfield twin column universal testing machine was used to mechanically test 
the nanocomposites with a 1 kN load cell and a 1 mm min–1 strain rate in accordance with 
ISO–527. Test specimens (number of specimens per material (n) ≥ 4) were punched from 
nanocomposite film and were dog-bone shaped (22 mm long, 2.7 mm wide, and 1 mm thick). 
Electrical conductivity (DC) was measured with an Agilent Technologies 34401A digital 
multimeter (n ≥ 3) with electrode contact points painted using silver paint (RS 186–3600) and 
applied voltage of 100 mV. Mass loss due to enzymatic biodegradation over 8 weeks of 
nanocomposite specimens (n = 5) in 37 oC PBS solution (pH = 7.4) with a 1.5 µg ml–1 
concentration of lysozyme [24], was recorded with an analytical balance (Sartorius M-power 
AZ124) and a Stuart SI500 bioincubator agitating at 100 rpm. After each time step, the 
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specimens were washed with distilled water and dried in a vacuum oven overnight before 
weighing, after which they were placed into fresh PBS and lysozyme solution. 
Production of nanocomposite microneedle arrays  
The microneedle male mould was produced in a “Multijet Modelling” system by Shapeways 
(U.S.A.) from UV cured acrylic polymer. Female replicated moulds were created by 
replicating the male mould with silicone (Techsil RTV2420).  
 Conventional microneedle arrays were created in a two-step process as outlined in 
figure 1 [11,15], with the filling of the main needle shaft and the filling of the needle base as 
two separate processes. First, viscous nanocomposite solution (~80 mg ml–1) was used to fill 
the moulds (figure 1A–2). To ensure that the solution filled the full microneedle (tip and 
shaft), the moulds were centrifuged at 8000 rpm for 1 h. Excess solution was cleaned from 
the surface and the moulds were left to air dry (figure 1A–3). The process of filling, 
centrifuging and drying the mould was repeated twice more to ensure the shaft was fully 
formed (figure 1A–(4–7)). Secondly, the base was filled with a viscous pristine chitosan 
solution, centrifuged for 1 h at 8000 rpm and dried in a vacuum oven (figure 1A–8). Upon 
drying, the microneedles were gently removed from the female mould and stored in 
desiccators.  
 Detachable microneedle arrays (figure 1B) were created with a ring of PEG at the 
base of the shaft. In an additional step to creating the standard microneedle arrays, after the 
microneedle shaft has been filled with the nanocomposite mixture and dried, a highly viscous 
water solution of PEG was applied to the mould and excess solution scraped off (figure 1B–
8). The moulds were then centrifuged for 1 h at 8000 rpm and dried in a vacuum oven (figure 
1B–9). The base of the microneedles was created as standard, i.e. filled with high viscosity 
pristine chitosan solution, centrifuged for 1 h at 8000 rpm and dried in a vacuum oven. 
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Characterisation of microneedles 
A Swift M10L microscope was used for optical microscopy images. Compression testing of 
the microneedles was carried out with a Hounsfield twin column universal testing machine 
with a 10 N load cell. The compression rate was 1 mm min–1. Two metal plates were used as 
the platens; the microneedle array was attached to a fixed platen and a second platen was 
attached to the load cell and was used to uniformly compress the microneedle arrays (n = 5) 
[25]. The penetration of the microneedle arrays was measured in full–thickness chicken skin 
[26] by cross-sectioning the specimen using a Brunel bench microtome after they were 
embedded in a Labonord Q-Path paraffin embedding medium.  
Chitosan–2 wt.% MGQD–LH microneedle arrays (n = 5) were placed in 30 ml of 
PBS solution (37 oC, pH = 7.4) and agitated at 100 rpm. LH drug release was measured at set 
time points by collecting 3 ml of the solution and analysing it with UV-Vis spectroscopy 
(Perkin Elmer Lambda 900 operating at a resolution of 1nm), having replaced the taken 
solution with 3 ml of fresh PBS. The curves for each time point were compared to curves of 
free LH in PBS of known concentrations.  
 Chitosan–2 wt.% MGQD–BSA microneedle arrays were tested in parallel for both 
passive diffusion and electrically stimulated diffusion of MGQD–BSA. For passive diffusion, 
the microneedle array (n = 3) was placed in 100 ml of distilled water (37 oC). BSA drug 
release was measured using UV-Vis spectroscopy, similar to the procedure to measure LH 
release. Electrically stimulated testing of the microneedles was described previously [15]. 
Briefly, microneedle arrays were mounted to a microscopy slide using double-sided tape and 
contacts were made with silver paint. The circuit consisted of a prototyping circuit board, a 
PP3 9 V 280 mAH nickel-metal hydride battery, a 2 kΩ resistor, an on/off switch, and two 
electrodes. A crocodile clip connected the silver paint contacts to the circuit. The second 
electrode was submerged in the container of distilled water. The glass slide was submerged 
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vertically to a point where only the microneedle array was in the water and not the silver 
paint or the crocodile clip. The electrical flow, therefore, was through the microneedle array 
and not through the crocodile clip or the silver paint.   
Statistical analysis 
MatLab 2012a software was used for statistical analysis (t-test, p < 0.05) and graphing. 
Results and discussion 
Characterisation of nanocomposites 
Characterisation of the MGQD nanoparticles has been reported before [3], and have been 
shown to possess photoluminescent and superparamagnetic properties for fluorescent 
imaging, magnetic resonance imaging (MRI) and responses to external magnetic stimulation. 
The MGQDs were ~40 nm in diameter and 2–2.5 nm high, and consisted of a GQD core 
coated with a shell containing a mixture of several iron oxides, namely maghemite, magnetite 
and hematite.  
MGQDs were dispersed within chitosan at concentrations of 0.25–5 wt.%. FT-IR 
spectra are shown in figure 2A, showing the characteristic peaks of chitosan (N–H peaks at 
2800 cm–1, C=O peak at 1720 cm–1, C=C peak at 1640 cm–1, amino peak at 1535–1546 cm–1, 
C–OH peak at 1405 cm–1 and C–O at 1050–1100 cm–1) [27]. The characteristic peaks of 
MGQDs are shown as C=C at 1564 cm–1, O–C=O at 1406 cm–1, and C–Fe peaks at 1086 cm–
1
 and 1012 cm–1 [3,28]. When MGQDs are added to chitosan, the amino peak shifts from 
1545 cm–1 for pristine chitosan to 1538 cm–1 for 1 wt.% MGQD, the C=C peak shifts from 
1636 cm–1 to 1631 cm–1 and the C–O peak shifts from 1060 cm–1 to 1063 cm–1. These shifts 
can be attributed to both the hydrogen bonding that occurs between the chitosan (amino 
group) [27] and the MGQDs (Fe–O and O–C=O) [3], and for the C–O peak shift there is the 
possible overlapping of peaks between the C–O peaks of chitosan and the C–Fe peaks of the 
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MGQDs. The shifts are accompanied by an increase in intensity of the C=C, amino, C–OH 
and C–O peaks for the 0.25 wt.% to 2 wt.% MGQD nanocomposites. 
In figure 2B, XRD traces of the nanocomposites can be seen. Typically, the chitosan 
peaks (crystalline and amorphous) are the only peaks present for both the pristine chitosan 
and the nanocomposites up to 2 wt.% MGQDs. The diffraction peaks from the MGQDs can 
be seen in the 5 wt.% nanocomposite due to the relatively high wt.% of MGQDs present. 
These peaks are the (213) peak from maghemite, (104) from hematite, and (422) and (511) 
from magnetite [3]. The other MGQD specific peaks may be present but too weak to clearly 
identify at this wt.%. From the chitosan-specific crystalline peaks that are identified on curve 
1 of figure 2B, the crystallinity (χc) can be determined from Equation 1 [29,30]: 
 
where IC and IA are the peak integrated intensities of the crystalline and amorphous regions, 
respectively [31,32]. This gives crystallinity values for 0–5 wt.% MGQDs nanocomposites of 
34.1%, 27.3%, 27.3%, 27.1%, 26.3% and 25.5% respectively, showing a decrease in 
crystallinity with increasing wt.% of MGQDs. Graphene based nanoparticles have been 
shown previously to reduce the crystallinity of some semicrystalline polymers [10,33], 
presumably due to graphene restricting the polymer chain rearrangement due to the surface 
absorption and bonding [33]. 
The electrical conductivity of the nanocomposites was measured, with a maximum 
conductivity of 3.3 x 10–3 S m–1 achieved at 5 wt.% MGQD versus 1.5 x 10–3 S m–1 for 
pristine chitosan (figure 2C). There was no significant increase in conductivity when the 
MGQDs wt.% increased from 0.25 wt.% to 2 wt.% MGQDs. The conductivity of the 5 wt.% 
MGQD nanocomposite is lower than that recorded for chitosan−GQD nanocomposites (e.g. 1 
12 
 
wt.% GQD = 1.61 x 10–2 S m–1) [15]. The difference between nanocomposites formed of 
highly-reduced GQD and of MGQD is due to the presence of IO on the surface of the 
MGQDs. IO can improve the conductivity of polymers [34], but graphene is more conductive 
than IO [35]. The shape, size, the dispersion degree of the MGQD and the volume fraction of 
graphene in the nanocomposite are other important factors that affect the electrical 
conductivity of a nanocomposite [36]. As conductive fillers, MGQDs are not as effective as 
GQDs, also due to MGQDs being both thicker than GQDs at ~2.5 nm [3] versus ~1.5 nm 
[15] and of a higher density than the GQDs which means that there is a lower volume fraction 
of MGQDs within the nanocomposite for a given wt.% (3.66 g cm–3 for MGQD in 
comparison to 1.66 g cm–3 for GQD [3]). The 5 wt.% MGQD nanocomposite, although the 
most conductive with a 94% increase over pristine chitosan and with the highest wt.% of 
MGQDs for drug delivery, was found to be too brittle to be mechanically tested.  
Figure 3A shows representative tensile stress-strain curves for pristine chitosan and 
chitosan nanocomposites. The Young’s modulus (E) is 1.48 (± 0.38) GPa, the ultimate tensile 
strength (UTS) is 62.5 (± 9.4) MPa, and elongation to break (εb) is 15.5 (± 4.2) % for pristine 
chitosan [15]. The 0.5 wt.% and 1 wt.% MGQD nanocomposites can be seen to have a lower 
UTS than pristine chitosan, with average values of 48.9 (± 3.4) MPa and 49.8 (± 4.1) MPa, 
respectively. The E of the 0.5 wt.% and 1 wt.% MGQD nanocomposites are 1.19 (± 0.07) 
GPa and 1.32 (± 0.16) GPa respectively. The 2 wt.% MGQD nanocomposite has a UTS and 
E that is statistically similar to pristine chitosan, with an E of 1.45 (± 0.27) GPa and a UTS of 
60.6 (± 7.3) MPa.  
The influential factors are the crystallinity of the chitosan and the effectiveness of the 
MGQD as reinforcing nanofillers. The crystallinity of a polymer can affect its mechanical 
properties [37], and the nanocomposites of 0.25–5 wt.% have a lower crystallinity than the 
pristine chitosan, potentially reducing the strength and stiffness of the nanocomposites. As 
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discussed previously, MGQD may not be as effective a nanofiller as GO or rGO due to its 
smaller aspect ratio (it has a smaller diameter than GO or rGO and is thicker than GO at ~2.5 
nm [3] versus ~1 nm [10]). It is also denser than rGO (1.46 g cm–3 [11]) which means that 
there is a lower volume fraction of MGQD nanoparticles within the nanocomposite for a 
given wt.% of nanofiller. MGQD does, however, have a rGO backbone (reported E of 250 
GPa [38]) and a shell of IO (E reported as 200–250 GPa depending on the crystal orientation 
[39]). There is also a relatively strong bonding between the MGQD and the chitosan as 
discussed before. However, the effectiveness of MGQD being a reinforcing nanofiller is 
cancelled out by the decrease in crystallinity in the case of the 2 wt.% nanocomposite, and is 
overshadowed by the latter in the cases of the nanocomposite with lower wt.% MGQD. The 
εb is 13.3 (± 3.9) % for 0.5 wt.%, 15.5 (± 4.5) % for 1 wt.%, and 18.2 (± 4.6) % for 2 wt.% 
MGQD nanocomposites. The slight increase in εb for the 2 wt.% MGQD nanocomposite can 
be explained by the reduction in the crystallinity of the chitosan in the nanocomposite and 
that the MGQD may possess a degree of mobility within the nanocomposite when the 
nanocomposite is under tension, which will absorb energy [40,41].  
Pristine chitosan and the 0.5–2 wt.% nanocomposites were subjected to a 
biodegradation test to determine the effect of MGQD concentration on the biodegradation 
rate of chitosan. Figure 3B shows the effect that increasing the MGQD concentration has 
upon the remaining mass of chitosan at each time-step when subjected to enzymatic 
biodegradation. Lysozyme is a natural enzyme and degrades the acetyl units of chitosan 
through hydrolysis of the β-glycosidic linkages [42,43]. Chitosan samples were reduced to 
61.6% of their original mass after 49 days, while 0.5 wt.%, 1 wt.% and 2 wt.% were reduced 
to 54.1%, 53.8% and 56.2% respectively.  
It was previously noted that the inclusion of graphene nanosheets impeded the 
biodegradation rate of nanocomposites [10,11,44] through the “tortuous path” model [45,46]; 
14 
 
this model proposes that high aspect ratio nanosheets that are well dispersed within the 
polymer matrix would pose a barrier to the permeation of gases or liquids into the matrix 
[45,46]. This was not the case with the MGQDs with a lower aspect ratio, as the 
nanocomposites can be seen in figure 3B to have a higher biodegradation rate than pristine 
chitosan and therefore the MGQDs did not impede the enzyme from permeating through the 
chitosan, similar to our previous work on chitosan−GQD nanocomposites which also contain 
low–aspect–ratio GQDs [15]. For the chitosan−MGQD nanocomposites, the difference in the 
final mass of the samples is statistically insignificant, showing that the biodegradation rate is 
not concentration dependent. The decrease in remaining mass between pristine chitosan and 
the MGQD nanocomposites is due to the lower crystallinity of the nanocomposites compared 
to pristine chitosan and the possible diffusion of some of the MGQDs from the 
nanocomposite into the PBS solution [47,48].  
The 2 wt.% MGQD nanocomposite was selected for use as a microneedle array as the 
nanocomposite had better mechanical properties than the other nanocomposites, while the 
high wt.% did not hinder the biodegradation characteristics (figure 3B) and would allow for a 
higher quantity of drug to be loaded into the nanocomposite relative to lower wt.% 
nanocomposites.  
Chitosan–2 wt.% microneedle arrays  
Chitosan–2 wt.% MGQDs nanocomposites were used to form microneedle arrays for the 
delivery of small and large MWt drugs into the body via transdermal drug delivery. 
Previously, it was shown that MGQDs were not cytotoxic to fibroblasts up to a concentration 
of 50 µg ml–1 after 24 h’s incubation [3]. Further improvements in cell viability may occur by 
coating MGQDs by chitosan, similar to the effect that coating GQDs with amine groups and 
IO by pullulan had [49,50]. Additionally, steam sterilisation/autoclaving has been shown to 
have minimal effect on chitosan, therefore preserving the chitosan structure within the 
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microneedle [51]. Figure 4A and 4B show optical micrographs of the chitosan–2 wt.% 
MGQD microneedle array (from here on known as CH–MGQD microneedle array), showing 
the plan and side profile of the microneedle arrays. Their structural integrity under the force 
of insertion (1.6 N for the microneedle array) [52,53] was verified by compression testing, as 
seen in figure 4C. A failure would be seen as a substantial drop in the compressive force 
required to compress the microneedle array. The inset of figure 4C shows that the CH–
MGQD microneedle arrays were strong enough to survive insertion into chicken skin by 
hand. The depth of penetration of the microneedle array into the chicken skin can be 
determined as approximately 500 µm, similar to previously reported penetration values for 
chitosan–GQD microneedles [15].  
To allow for the microneedles to detach from the microneedle array base, a disc of the 
water soluble polymer PEG was included at the base of the microneedle shaft. Different MWt 
PEG polymers (10k, 20k and 35k) were investigated for their effect on the structural integrity 
of the microneedle arrays. Higher MWt PEG was not tested as both the systemic clearance of 
PEG from the body [54] and the dissolution rate [55] are reduced as the MWt increases. 
Figure 5A shows representative curves of the compressive testing of pristine chitosan 
microneedle arrays with a small ring of PEG between the main microneedle shaft and the 
base. The 10k PEG microneedle array deformed substantially in comparison to pristine 
chitosan; the low MWt PEG offered limited mechanical strength to the base of the 
microneedle when under compression. In contrast, the 20k PEG microneedle arrays retained 
similar levels of deformation to the pristine chitosan sample due to the stronger 20k PEG 
relative to the 10k PEG.  
The microneedle arrays containing 35k PEG were less ductile than the pristine 
chitosan microneedle arrays, due again to the rigidity of the high MWt PEG. A strong base is 
important to prevent the fracture or bending during insertion. The 35k PEG was the strongest 
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base material and the force versus displacement curve was similar to the chitosan–2 wt.% 
MGQD microneedle array in figure 4C. The 35k PEG was chosen to be used in this 
nanocomposite microneedle array.   
The compressive testing results of the CH–MGQD with 35k PEG (from here on 
known as CH–MGQD–PEG) microneedle arrays are shown in figure 5B, which shows that 
the addition of a PEG ring to the base of the microneedle main shaft does not deteriorate the 
strength of the microneedle array in comparison to conventional CH–MGQD microneedle 
arrays. 
Figure 6 shows the detachment of the microneedle main shaft from the array base; the 
CH–MGQD–PEG microneedle array was mounted to a glass slide and two drops of distilled 
water were applied to the upper surface. After 5 min, the water had caused the microneedle to 
swell and upon further inspection the microneedle shafts were no longer connected to the 
microneedle base. The mounds at the base of the microneedle shaft can be seen to have 
remained, as seen in figure 6B and measuring 310 µm in diameter. The region where PEG 
was deposited would have been between the mound and the main shaft. This shows that the 
microneedles can be detached within 5 min when in the presence of water or bodily fluid 
within skins by placing a ring of PEG between the main shaft and the base. As a further proof 
of concept test, the CH–MGQD–PEG microneedle array was inserted into chicken skin 
(figure 6C) for 5 min and the microneedles separated from the main base. This further 
confirms that the PEG separation method can work after insertion into skin.  
   For the delivery of small MWt therapeutics, LH (MWt = 288) was chosen as the 
model drug. The drug was bonded (via hydrogen bonding and π-π stacking) to the surface of 
the MGQDs, with a loading ratio of 0.31:1 (LH:MGQD) [3]. Microneedle arrays containing 
chitosan and 2 wt.% MGQD with bonded LH were tested for the release of LH (figure 7). 
Two types of microneedle arrays were tested; CH–MGQD–PEG and CH–MGQD. It can be 
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seen that the two types of microneedle array were initially (up to 4 h) very similar in terms of 
quantity of drug released and the rate at which it was released, after which the CH–MGQD–
PEG released less LH than the CH–MGQD microneedle array (after 7 h, CH–MGQD 
released 12.3 µg or 76.6% of the available drug and CH–MGQD–PEG released 9.4 µg or 
59.4%). After this time-point, the microneedles were no longer fully intact and the test was 
stopped.  
The difference in final delivery quantity is presumably due to the separation of the 
microneedles from the base, as the same amount of drug-containing chitosan–2wt.% MGQD 
was used in both types of microneedles (i.e. three centrifuge cycles) and therefore the results 
should be identical. It is possible that some of the microneedle shafts for the CH–MGQD–
PEG may have become buoyant after 4 h after detaching from the base and floated to the 
surface of the PBS, but this would not occur during in vivo treatment as the microneedles 
would be embedded in the skin prior to the separation. This test focused on the release of 
MGQD–LH from the microneedle array; it has been shown that bound, small MWt drugs like 
LH bound to MGQD [3] or FL bound to rGO [56] can be released from their nanoparticles 
over a period of time and the nanoparticles can be excreted from the body through urine [57]. 
To study the release of large MWt drugs from the CH–MGQD microneedles, 
MGQDs were bonded to the therapeutic BSA (~60k MWt). Iontophoresis could not be 
achieved with CH–MGQD–PEG microneedles as the PEG ring would cause the detachment 
of the main microneedle shaft before the drug could be released. Figure 8A shows the TGA 
curves of MGQDs, BSA, and MGQD–BSA. This shows that there is a 9.5%, or 0.10:1 
BSA:MGQD, loading of BSA in MGQD–BSA, as determined from the mass loss of MGQD–
BSA between 220–400 oC, accounting for both the loss of BSA over this temperature range 
(52.8%) and absorbed water. This MGQD–BSA was used to form CH–MGQD 
microneedles which were subsequently tested for passive diffusion release of BSA 
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over 1440 min (24 h), as shown in figure 8B. The release of BSA was limited, with only 
0.5 µg or 10.7% released after 9 h and 1.2 µg or 25.7% released over 24 h. Similar passive 
drug release performance from BSA loaded CH–MGQD–PEG microneedle array is 
expected. 
This low level of release can be improved by using electrical stimulation as 
shown previously for other therapeutic substances, through either electroporation (where 
the electrical stimulus increases the permeability of the cell membrane) or iontophoresis 
(where electrical stimulation creates an electo-repulsion of charged molecules or electro-
osmosis of molecules without a charge) [8, 58-60]. The use of electrical stimulation to 
improve the release of large MWt drugs was shown to be successful for 
chitosan−GQD microneedles, where there was a significant improvement over 
standard diffusion release of BSA from chitosan−GQD microneedles [15]. A similar 
improvement was noted for the CH–MGQD microneedles, with 1.9 µg or 40.7% released 
over 9 h and 4.5 µg or 96.4% released over 24 h, with the final value markedly higher than 
the 1.2 µg after 24 h for the passive diffusion microneedle array. Figure 8C shows the 
difference in release visually, with passive diffusion shown in the left container and 
electrically stimulated release in the right container. The yellow colour of the FL–
labelled BSA can be seen in the right container after 4 h, with the colour becoming 
more vibrant at 6 h and 8 h. After 24 h, the colour of the right container is a 
combination of the strong yellow from the FL release and the black of the MGQDs 
[3,15]. The water in the left container does not exhibit a strong yellow colour as the amount 
of BSA released from the passive diffusion microneedle array was substantially lower. The 
results of the drug test in figure 8B show that chitosan and 2 wt.% MGQD microneedle 
arrays can be used for the release of large MWt drugs through electrically stimulated 
diffusion; this ability is due to the nanocomposites being electrical conductive which 
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enables the current to flow through the nanocomposite in order to transfer the 
therapeutic from the nanocomposite into the target medium, such as with normal 
iontophoretic devices and their electrodes [60]. The results presented in figure 7 and 
figure 8 show that chitosan–MGQD nanocomposites are capable of the efficient and 
strong release of small and large MWt drugs when in the form of a microneedle array. 
Conclusions 
Quantum dots of iron oxide coated reduced graphene oxide were dispersed in chitosan 
to form nanocomposites for transdermal drug delivery applications. The presence of 2 
wt.% MGQDs in chitosan increased the electrical conductivity by 25%, which was 
crucial for the subsequent introduction of electrical simulation during drug delivery. It 
gave a statistically similar ultimate tensile strength and Young’s modulus to chitosan, 
partially attributable to its lower crystallinity. It also enhanced the biodegradation rate 
of chitosan slightly during the test period (within 7 weeks).   
The nanocomposites were formed into microneedle array by solution casting, 
and compression testing of the microneedles confirmed that they were strong enough 
to survive the force of insertion into the skin layers. To allow for the quick detachment 
of the main microneedle shaft from the array base, the microneedle arrays were 
manufactured to separate into two parts by the addition of a section of water soluble, 
biocompatible polymer (PEG) at the base of the microneedles. This allowed for the 
detachment of the microneedles within 5 min when in contact with water, but did not 
negatively impact the mechanical strength of the microneedles under compressive 
loading. The detached microneedle shaft can stay in the body while the base can be 
readily removed and sent to waste.  
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Both the conventional and the detachable microneedle array were tested for the 
release of a small molecular weight drug, with the former releasing 76.6% and the 
latter releasing 59.4% of the available drug within 7 h. There was a marked 
improvement in the delivery of large MWt drugs when the conventional microneedles 
were electrically stimulated to create a microneedle array-iontophoretic type device. 
The total percentage of drug released increased from 25.7% for passive diffusion to 
96.4% over 24 h for the iontophoretic type microneedle array, showing that the ability 
to efficiently release large MWt drugs from the nanocomposite was achievable by 
using electrical stimulation of the conductive microneedles.  
Microneedles prepared from chitosan–MGQD nanocomposites have great 
potential for use in medicine; the use of MGQDs as a drug carrier allows for 
therapeutics of small or large MWt to be bonded to the nanoparticle, subsequently 
targeted by an external magnetic field to a site of release whilst being monitored by 
MRI or fluorescent imaging. The electrical conductivity of chitosan–MGQD 
nanocomposites can be used for the electrically stimulated release of large MWt drugs, 
enabling chitosan–MGQD microneedle arrays to be used as a universal delivery 
platform for therapeutics of different sizes and their subsequent targeting and tracking. 
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Figure Captions 
Figure 1. Experimental procedure to create (A) conventional and (B) detachable 
chitosan–MGQD microneedle arrays. 
Figure 2. (A) FT–IR spectra, (B) XRD traces and (C) electrical conductivity of 
chitosan–MGQD nanocomposites.  
Figure 3. (A) Representative tensile testing curves and (B) biodegradation data for 
pristine chitosan and 0.5 wt.%, 1 wt.%, and 2 wt.% MGQD nanocomposites.  
Figure 4. Optical micrographs of the CH–MGQD microneedle array: (A) side view 
and (B) plan view, and (C) compression testing curves of CH–MGQD microneedle 
arrays. (Inset) side view of CH–MGQD microneedle array after insertion into chicken 
skin showing the penetration depth.  
Figure 5. Compression testing of (A) chitosan and various MWt PEGs and (B) CH–
MGQDs with 35k PEG microneedle arrays. 
Figure 6. Side view of a CH–MGQD–PEG microneedle array, (A) before and (B) 
after 5 min in the presence of water, showing the successful detachment of the 
microneedle shaft from the base. (C) After insertion of the microneedle array into 
chicken skin for 5 min, the successful detachment of the microneedle shaft from the 
base can be seen again. 
Figure 7. Release of LH from microneedle arrays of CH–MGQD or CH–MGQD–
PEG over 7 h. The release from both microneedles can be seen to be very similar in 
profile. 
Figure 8. (A) TGA curves showing the loading of BSA onto MGQDs, (B) the passive 
diffusion and electrically stimulated release of BSA from microneedle arrays, and (C) 
visual representation of the difference in release of BSA by either passive (left) or 
electrically stimulated (right) release.  
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